There were 217 press releases posted in the last 24 hours and 190,421 in the last 365 days.

Acute Kidney Injury Treatment Market to Surpass US$ 3,031.6 Million by 2028, Says Coherent Market Insights (CMI)

/EIN News/ -- SEATTLE, Oct. 14, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global acute kidney injury treatment Market is estimated to be valued at US$ 1,857.8 million in 2021 and is expected to exhibit a CAGR of 7.2% during the forecast period (2021-2028).

Key Trends and Analysis of the Global Acute Kidney Injury Treatment Market:

Key trends in the market include research and development for the treatment of acute kidney injury, which is expected to drive the global acute kidney injury treatment market growth over the forecast period. For instance, in July 2018, Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, announced the first patient dosed in the pivotal Phase III clinical trial of QPI-1002 a siRNA targeting p53, for the prevention of acute kidney injury and its consequences following cardiac surgery.

Furthermore, key players in the market are focusing on growth strategies such as distribution agreement, which is expected to boost the global acute kidney injury treatment market growth over the forecast period. For instance, in September 2020, Baxter International Inc., a global leader in acute care, announced a distribution agreement with bioMérieux, a global leader in in-vitro diagnostics, for the NEPHROCLEARTM CCL14 diagnostic test. The NEPHROCLEARTM CCL14 test is currently in development for use in assessing the risk of developing persistent severe acute kidney injury (AKI). The agreement is part of a previously announced collaboration between Baxter and bioMérieux to improve the identification and treatment of AKI.

Request for Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4691

Key Market Takeaways:

The global acute kidney injury treatment market is expected to exhibit a CAGR of 7.2% during the forecast period due to rising geriatric population is expected to drive the global acute kidney injury treatment market over the forecast period. For instance, according to the report published by the United Nation (UN) in 2017, the global population of age 60 and above was around 962 million, and is expected to reach 2.1 billion by 2050.

Among type, prerenal acute kidney injury segment is estimated to hold a dominant position in the global acute kidney injury treatment market over forecast period as pre-renal injury is more prevalent in patients with acute kidney injury. Increase in incidences of acute kidney injury cases is expected to drive the growth of the segment over forecast period. For instance, according to an article published in Karger Journals in 2016, stated that pooled incidence of acute kidney injury (AKI) in hospitalized patients using a kidney disease improving global outcomes (KDIGO)-equivalent AKI definition was 22.3% in North America, 31.0% in South America, and 16.9% in Australia and New Zealand, and varied between 19.3 and 25.2% in Europe.

On the basis of treatment, drugs segment is estimated to hold a dominant position in the global acute kidney injury treatment market over forecast period due to the presence of drugs such as recombinant alkaline phosphatase and nephrotoxic agents. Moreover, key companies in the market focusing on strategies such as fund raiser for the treatment of acute kidney injury, which is expected to drive the growth of the segment over forecast period. For instance, in March 2020, AM-Pharma B.V., a clinical stage biopharmaceutical company leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human Alkaline Phosphatase therapeutic (recAP), announced that they had raised additional funds of US$ 52 million, increasing the total recent fundraising to US$ 176 million. This fund raiser will be used to support a multi-national pivotal Phase III trial of recAP in 1,400 patients with sepsis-associated-acute kidney injury (SA-AKI).

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4691

Competitive Landscape:

Key players operating in the global acute kidney injury treatment market include Quark Pharmaceuticals, Inc.,  Baxter International, Inc., Novartis AG., B. Braun Melsungen AG,  Fresenius Medical Care, Medtronic, Astellas Pharma Inc., Sentien Biotechnologies, Inc., Teva Pharmaceutical Industries Ltd., Asahi Kasei Medical Co., AM-Pharma B.V, Teleflex Incorporated, Cure Medical, LLC, and Angion Biomedia Corp

Market Segmentation:

  • Global Acute Kidney Injury Treatment Market, By Type :
    • Prerenal Acute Kidney Injury
    • Intrinsic Renal Acute Kidney Injury
    • Postrenal Acute Kidney Injury
  • Global Acute Kidney Injury Treatment Market, By Treatment  :
    • Therapy
    • Drugs
  • Global Acute Kidney Injury Treatment Market, By Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Acute Kidney Injury Treatment Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa

Related Market Intelligence Reports:

Chronic Kidney Disease Drugs Market, by Drug Type (ACE Inhibitors, B-blockers, Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-stimulating Agents (ESAs), Phosphate Binders, and Others), by Route of Administration (Oral, Intravenous, and Subcutaneous), by Patient Type (Dialysis and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Kidney Dialysis Equipment Market, by Equipment (Hemodialysis (Hemodialysis Machines and Consumables), Peritoneal Dialysis (Peritoneal Dialysis Machines and Consumables), and Continuous Renal Replacement Therapy (CRRT)), by End User (Home Care Settings, Dialysis Centers, and Hospitals & Clinics), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Follow Us: LinkedInTwitter


Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights

Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com

Primary Logo